Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Non-Hodgkin lymphoma, adult
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 791 for your search:
Start Over
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: Hemato INCAN 01/2007, NCT00429065
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HEMOS ALL1105, NCT00797810
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-4438, B1771007, 2009-015498-11, NCT01180049
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Plerixafor-UF01, NCT01339572
Treatment of Natural Killer/T Cell Lymphoma-I/II
Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011, NCT01501136
Treatment of Natural Killer/T Cell Lymphoma-?/?
Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-2, NCT01501149
Treatment of Diffuse Large B Cell Lymphoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-4, NCT01949818
ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 2013(56), NCT02290132
Mature B-Cell Lymphoma And Leukemia Study III
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: SJBC3, NCT01046825
TREatment of degeNerative and Neoplastic Diseases With Rituximab
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRO-1908, PRO1908TREND, NCT01277172
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: Busulfan-2013, NCT01800643
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory DLBCL Patients Before High-Dose Chemotherapy BEAM With ASCT.
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: FIL_VERAL12, NCT01805557
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CCBX001-049, NCT00078598
Phase 3 BBR 2778 for Relapsed, Aggressive Non-Hodgkin’s Lymphoma (NHL)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PIX301, NCT00088530
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: DSHNHL 2002-1, NCT00129090
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL2004-1, NCT00209209
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MCL2004-2, NCT00209222
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: HELYX Study, NCT00154440
LMBA02 Protocol for Patients With a Burkitt Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LMBA02, NCT00180882
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CDR0000459685, DSHNHL-2004-2, EU-205110, EUDRACT-2005-00521738, DSHNHL-FLYER-6664, NCT00278421
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CDR0000459796, DSHNHL-2004-3, EUDRACT-2005-005218-19, EU-205111, NCT00278408
HuMax-CD20 in FL Patients Refractory to Rituximab
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Hx-CD20-405, GENMAB-Hx-CD20-405, OHSU-2634, NCT00394836
Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Sor451107ctil, NCT00463463
Start Over